Affimed N.V. - Common Stock (AFMD)

Competitors to Affimed N.V. - Common Stock (AFMD)

Amgen Inc. 

Amgen, a leader in biotechnology, competes with Affimed primarily in the development of immunotherapies and targeted treatments. Both companies are focused on leveraging the body's immune system to combat cancer, though Amgen has a broader portfolio of established therapies and significant resources for research and development. This extensive pipeline and commercial presence give Amgen a competitive edge in attracting partnerships and investments.

Bristol-Myers Squibb Company 

Bristol-Myers Squibb (BMS) competes with Affimed in the oncology market, particularly with their focus on immuno-oncology therapies such as checkpoint inhibitors and proprietary biologics. BMS benefits from a strong established brand, a diverse portfolio, and significant resources allocated for clinical trials, providing them with advantages in market penetration and patient access. In contrast, Affimed's focus on innovative antibody formats presents a niche opportunity in a highly competitive environment.

Genentech, a member of Roche

Genentech, owned by Roche, is a leading player in the oncology space with a suite of successful biologics, including HER2 therapies and new targeted treatments. They compete directly with Affimed on innovative cancer therapies that harness the immune system. Genentech's longstanding reputation, extensive pipeline, and significant revenue streams from existing products provide a competitive advantage in funding new research, particularly in rapidly evolving areas like immunotherapy.

Gilead Sciences, Inc. 

Gilead Sciences is an established biopharmaceutical company that has made significant inroads into oncology with its CAR-T and other immune-oncology therapies. While Affimed is more specialized in bispecific antibody formats, Gilead leverages its extensive experience in both virology and oncology platforms, along with a robust financial position that allows for aggressive development and marketing strategies in the cancer therapeutics sector.

MacroGenics, Inc. 

MacroGenics focuses on developing monoclonal antibodies for cancer treatment, competing in similar therapeutic areas as Affimed. Both companies are innovating in treatments that target immune pathways to improve responses in cancer patients. However, MacroGenics has established partnerships that provide additional funding and infrastructure support, giving it an edge in advancing its pipeline more robustly compared to Affimed's smaller operations.